Landmark Study Uncovers Widespread Undiagnosed Heart Failure in Diabetic Population
A groundbreaking medical trial has revealed that a substantial proportion of individuals living with diabetes may be suffering from undiagnosed heart failure, a serious condition that could be identified through straightforward screening methods. The TARTAN-HF trial, a significant research initiative, found that approximately one in four diabetic patients, particularly those with additional heart failure risk factors, had the condition without prior detection.
Simple Blood Test and Ultrasound Screening Prove Effective
The study, which commenced over three years ago, involved more than 700 participants with diabetes from NHS Greater Glasgow & Clyde and NHS Lanarkshire health board areas. These individuals all possessed at least one other risk factor for heart failure. Researchers employed a combination of the widely available NT-proBNP blood test, which measures cardiac strain, and heart ultrasound imaging to conduct screenings.
Participants were randomly assigned to either receive this heart failure screening or continue with their standard medical care. The results were striking: within six months, screening uncovered heart failure in nearly 25% (24.9%) of those tested. In stark contrast, only 1% of the group receiving usual care were diagnosed with the condition during the same period.
Clinical Implications and Expert Commentary
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular & Metabolic Health, who led the study, emphasised the importance of these findings. "Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients," he stated.
Dr Docherty further explained that many symptoms and signs of heart failure are non-specific and may go unrecognised for extended periods. "The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure," he added.
Collaborative Research and Broader Impact
The University of Glasgow conducted this research in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, and the two NHS health boards. The study included patients with both type 1 and type 2 diabetes, and researchers noted that almost all participants found to have heart failure had preserved ejection fraction, a form that can be challenging to detect without dedicated testing.
Dr Edward Piper, medical director at AstraZeneca UK, commented on the implications: "Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy."
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, highlighted the diagnostic advancements: "We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test. By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives."
Presentation and Future Directions
The findings were presented at the American College of Cardiology conference in New Orleans, USA, which took place from March 28 to 30. Medical experts suggest that implementing a systematic heart failure screening programme for diabetic patients could significantly improve diagnosis rates, lead to earlier treatment initiation, and potentially reduce hospitalisations and mortality associated with the condition.
This research underscores a critical gap in current healthcare practices and points toward a simple, actionable solution that could enhance the management of diabetes and its cardiovascular complications across the United Kingdom and beyond.
